Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of Endostar plus capecitabine combined with stereotactic radiotherapy in the treatment of advanced pancreatic cancer subjects open, single group phase II

X
Trial Profile

Clinical study of Endostar plus capecitabine combined with stereotactic radiotherapy in the treatment of advanced pancreatic cancer subjects open, single group phase II

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Endostatin (Primary) ; Capecitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2016 Status changed from recruiting to completed, as reported by Chinese Clinical Trial Registry.
    • 02 Jun 2015 Interim results in 13 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 30 Oct 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top